14,000 Shares in IDEXX Laboratories, Inc. $IDXX Purchased by Strs Ohio

Strs Ohio bought a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 14,000 shares of the company’s stock, valued at approximately $5,879,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Sage Mountain Advisors LLC grew its stake in shares of IDEXX Laboratories by 3.8% during the first quarter. Sage Mountain Advisors LLC now owns 635 shares of the company’s stock valued at $267,000 after buying an additional 23 shares during the last quarter. Great Lakes Advisors LLC grew its stake in IDEXX Laboratories by 0.9% in the first quarter. Great Lakes Advisors LLC now owns 2,567 shares of the company’s stock worth $1,078,000 after purchasing an additional 23 shares in the last quarter. PDS Planning Inc boosted its position in IDEXX Laboratories by 3.9% during the 1st quarter. PDS Planning Inc now owns 641 shares of the company’s stock valued at $269,000 after acquiring an additional 24 shares in the last quarter. King Luther Capital Management Corp boosted its position in IDEXX Laboratories by 0.5% during the 1st quarter. King Luther Capital Management Corp now owns 4,896 shares of the company’s stock valued at $2,056,000 after acquiring an additional 24 shares in the last quarter. Finally, Bigelow Investment Advisors LLC boosted its position in IDEXX Laboratories by 1.9% during the 1st quarter. Bigelow Investment Advisors LLC now owns 1,420 shares of the company’s stock valued at $596,000 after acquiring an additional 27 shares in the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Michael Lane sold 8,411 shares of the company’s stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $627.74, for a total transaction of $5,279,921.14. Following the transaction, the executive vice president directly owned 7,132 shares in the company, valued at $4,477,041.68. This represents a 54.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Nimrata Hunt sold 7,143 shares of the company’s stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $630.43, for a total value of $4,503,161.49. Following the transaction, the executive vice president owned 18,007 shares in the company, valued at $11,352,153.01. This trade represents a 28.40% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 54,057 shares of company stock valued at $34,293,468 over the last ninety days. 0.98% of the stock is owned by insiders.

IDEXX Laboratories Trading Down 0.6%

IDXX opened at $641.14 on Monday. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $688.12. The stock has a market capitalization of $51.29 billion, a PE ratio of 53.38, a P/E/G ratio of 4.15 and a beta of 1.56. The business’s 50 day moving average price is $603.59 and its 200 day moving average price is $514.19. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Monday, August 4th. The company reported $3.63 EPS for the quarter, beating analysts’ consensus estimates of $3.28 by $0.35. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The firm had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.06 billion. During the same period in the prior year, the firm posted $2.44 earnings per share. The firm’s quarterly revenue was up 10.6% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. As a group, equities research analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Stifel Nicolaus set a $640.00 price objective on IDEXX Laboratories in a research report on Monday, August 4th. Jefferies Financial Group initiated coverage on IDEXX Laboratories in a report on Tuesday, July 1st. They issued a “buy” rating and a $625.00 price objective for the company. Wall Street Zen raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Saturday, July 12th. Piper Sandler reissued a “neutral” rating and issued a $700.00 price objective (up previously from $510.00) on shares of IDEXX Laboratories in a report on Monday, August 11th. Finally, Morgan Stanley lifted their price target on IDEXX Laboratories from $722.00 to $765.00 and gave the company an “overweight” rating in a research note on Friday, August 15th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $649.44.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.